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Abstract
Education
Introduction
Sarcoidosis was originally described by the English physician 
Jonathan Hutchinson in 1869 as a disorder of the skin.1 It 
is now known that sarcoidosis is a multisystem disorder, 
characterised by granulomatous infl ammation for which no 
other cause has been identifi ed. Diagnosis and treatment 
of sarcoidosis remain challenging.2,3 While its aetiology and 
immunopathogenesis are still poorly understood, the last 
decade has brought considerable advances in managing 
sarcoidosis: endobronchial ultrasound (EBUS)-guided lymph 
node sampling is now routine, and 18F-fl urodeoxyglucose 
(18F-FDG) positron emission tomography (PET) scanning is 
sometimes used in selected cases. Furthermore, although 
corticosteroids remain a cornerstone treatment, newer 
‘steroid-sparing’ therapies, such as biologics, can be used 
to treat sarcoidosis.4 In this evidence-based and practical 
review, we use clinical vignettes to discuss diagnostic and 
therapeutic advances and some updates from the recent 
clinical guidelines. 
Search strategy
We based our review on national and international 
guidelines,5,6 in addition to searching PubMed and Medline 
using the terms ‘sarcoidosis’, ‘endobronchial ultrasound’, 
‘positron emission tomography’, ‘biologics’ in various 
combinations. We also searched publications cited in 
bibliographies of articles.4
 Case scenario 1
A 28-year-old non-smoker has an incidental finding of 
bilateral hilar lymphadenopathy (BHL) on her chest 
radiograph. A month earlier she presented with malaise, 
painful ankles and lower limb bruises. She is now 
asymptomatic, but anxious to know whether she could have 
cancer. Does she need a bronchoscopy?
Bilateral hilar and right paratracheal lymphadenopathy are 
common radiographic fi ndings (Figure 1) in asymptomatic 
sarcoidosis (stage I disease; Box 1). These are often 
incidental fi ndings and remain undetected until a chest 
radiograph is performed, usually for another reason. In this 
case, imaging was appropriately requested based on the 
classical presentation of sarcoidosis as Löfgren syndrome: 
erythema nodosum (EN), ankle arthralgia, and constitutional 
symptoms (malaise, fever, sweating and weight loss) which 
are associated with BHL.
The finding of BHL often results in significant anxiety 
around the possibility of cancer.4 While there are many 
underlying causes of BHL, important differentials include 
sarcoidosis, tuberculosis and lymphoma (Table 1). Although 
an absolute diagnosis of sarcoidosis requires a tissue biopsy 
(demonstrating non-caseating granulomatous infl ammation 
with no alternative causes), a presumptive ‘clinical’ 
diagnosis is often appropriate, combined with subsequent 
review. Biopsy is only required if atypical features such as 
progressive respiratory symptoms emerge during follow-up.8 
Sarcoidosis remains dif cult to diagnose, assess and treat. The last decade 
has brought signi cant diagnostic and therapeutic advances in the  eld 
of sarcoidosis including endobronchial ultrasound, 18F-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• Stage I: Lymphadenopathy alone – excellent outcome
• Stage II: Pulmonary infi ltrates with lymphadenopathy 
– progression in 1/3 at 5 years
• Stage I I I :  Pulmonar y inf i l t rates without 
lymphadenopathy – progression in 2/3 at 5 years
• Stage IV: Pulmonary fi brosis – signifi cant morbidity 
and mortality
Box 1 Scadding radiographic staging of sarcoidosis7
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Clinicians and patients will have their own views as to whether 
they wish to pursue a tissue diagnosis, and an individualised 
collaborative pro vs con discussion is recommended. 
Bronchoscopy under local anaesthetic is usually safe and well 
tolerated but can be unpleasant for patients. In asymptomatic 
individuals with BHL, particularly those with EN, sarcoidosis is 
usually the most likely cause, and a ‘wait-and-watch’ approach 
with further chest radiography is acceptable. Nonetheless, 
some patients may not be entirely reassured and request as 
much certainty as possible. In these patients a bronchoscopy 
with endobronchial ultrasound-guided transbronchial needle 
aspiration (EBUS-TBNA) can be useful and obviate the need 
for mediastinoscopy. 
Outcome
A full history was taken and the patient was completely 
asymptomatic. There were no features of infection or 
malignancy. She was on no regular medications, had no family 
history of lung disease and no relevant exposure to domestic, 
environmental or occupational dusts. Clinical examination 
was normal. Blood tests were unremarkable apart from 
mild lymphopenia, electrocardiogram (ECG) was normal and 
high-resolution CT (HRCT) scan noted mediastinal and right 
paratracheal lymphadenopathy, consistent with sarcoidosis, 
and not typical of lymphoma. No hepatosplenomegaly was 
seen. Her tuberculin skin test was negative and lung function 
tests were normal. In view of these fi ndings, she agreed 
with her clinician that the likelihood of having an alternative 
diagnosis to sarcoidosis was low. She continued to be 
reviewed at six-monthly intervals for two years, during which 
her BHL gradually resolved on chest radiograph, and she was 
subsequently discharged. 
Case scenario 2
A 49-year-old man presents with a two-month history of 
malaise, cough, breathlessness and 3 kg weight loss. 
He is a non-smoker with no notable past medical history. 
Clinical examination is normal, but his chest radiograph 
and subsequent HRCT are suggestive of stage II pulmonary 
sarcoidosis. You are keen to make a confi dent diagnosis – 
how should he be assessed? 
There is no single diagnostic test for sarcoidosis. Rather, 
three diagnostic criteria are used:
1. compatible clinical and radiological features
2. compatible histological fi ndings on biopsy
3. exclusion of differential diagnoses
The respective weighting for each criterion will vary with the 
clinical presentation. For example, Löfgren’s syndrome, as 
in our fi rst case, is a strong predictor of the diagnosis of 
sarcoidosis with a positive predictive value of 75%, precluding 
the need for a biopsy in typical cases.9 Advances are being 
made in developing diagnostic and prognostic biomarkers for 
sarcoidosis; however, these are yet to be incorporated into 
routine clinical practice.3,10–12 
Initial investigations
A variety of investigations may be decisive in altering the 
diagnostic probabilities of sarcoidosis:
Chest radiography: This is an important initial investigation 
that should be performed in all patients with suspected 
sarcoidosis. Around 90% of patients presenting with pulmonary 
sarcoidosis will have an abnormal chest radiograph.13
Blood tests: A full blood count will typically show lymphopenia, 
since lymphocytes are usually sequestered centrally in the 
lungs, with relative peripheral depletion in blood. Urea and 
creatinine, or liver function tests may be deranged in renal or 
liver involvement, respectively. Macrophage activity in sarcoid 
granulomas can lead to hypercalcaemia due to altered 
Vitamin D and calcium metabolism.14
Immunoglobulins: Measurement of serum immunoglobulins 
can differentiate sarcoidosis from common variable 
immune deficiency, which typically demonstrates 
hypogammaglobulinaemia and can mimic sarcoidosis with 
a granulomatous pneumonitis. While rare, this is important 
not to miss since the management is signifi cantly different. 
Human immunodefi ciency virus (HIV): HIV infection should 
always be excluded as both sarcoidosis and HIV can present 
with interstitial lung shadowing and lymphopenia.
 Figure 1 Bilateral hilar lymphadenopathy on a chest radiograph52 
Granulomatous Sarcoidosis
Infections Tuberculosis, histoplasmosis, 
coccidioidomycosis.
Malignancy Lymphoma, carcinoma
Inorganic dust disease Silicosis, berylliosis
Reactive Congestive cardiac failure
Table 1 Differential diagnosis of bilateral hilar lymphadenopathy 
(BHL)
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Serum angiotensin converting enzyme (ACE): This is a 
controversial test. ACE can be elevated in sarcoidosis but 
has a diagnostic sensitivity of only 60% and poor specifi city 
– an elevated ACE can be found in many conditions including 
tuberculosis, hyperthyroidism, alcoholic liver disease, 
diabetes and lymphoma.5,15 Furthermore, the concomitant 
use of an ACE inhibitor reduces ACE levels and genetic 
polymorphisms can lead to significant inter-individual 
variability.16 In 2008 the British Thoracic Society (BTS) 
suggested routine measurement of serum ACE was not 
required.5 However, in 2020 the latest BTS guidelines (in 
draft format only) suggest ACE should be routinely checked 
as elevated levels may correlate with disease activity and 
potentially help during follow-up.4
Urine investigations: Urine dipstick, assessing for proteinuria 
and haematuria, should be performed in all patients with lung 
infi ltrates, to help rule out vasculitides.
Spirometry should be performed in all patients with 
pulmonary symptoms and an ECG is useful to assess for 
cardiac involvement. Due to the risk of sight-threatening 
complications, all patients with suspected sarcoidosis should 
undergo formal ophthalmological evaluation.5
Tuberculin skin test: This test is typically negative in 
sarcoidosis due to pulmonary sequestration of peripheral 
T-lymphocytes.17 A positive test suggests that tuberculosis 
must be actively excluded.
Imaging
While a chest radiograph can be diagnostic in the appropriate 
context, HRCT better delineates the extent of disease 
and potential biopsy sites. Typical HRCT fi ndings include 
parenchymal nodularity (correlating with granulomas on 
pathology) along the bronchovascular bundles, interlobular 
septa and subpleural regions.18,19 Features of pulmonary 
fibrosis may be seen in advanced disease and cystic 
architectural distortion suggests irreversible disease.20 
Notably, sarcoidosis can cause a range of atypical HRCT 
features which can lead to diagnostic challenges.21
Biopsy and bronchoscopy
The pathological hallmark of sarcoidosis is non-caseating 
granulomas consisting of multinucleated giant cells 
associated with a chronic lymphocytic infi ltrate and varying 
degrees of fi brosis. Although the diagnosis of sarcoidosis 
is most secure in the context of a tissue diagnosis, non-
caseating granulomas are neither specifi c nor diagnostic of 
sarcoidosis as they may be seen in other conditions (Figure 
2).17 This highlights the importance of a thorough clinical 
assessment and exclusion of other diagnostic possibilities. 
The choice of biopsy site is infl uenced by organ involvement 
and the ease of access.22 Skin biopsies are technically easy 
to perform and sarcoidosis has a predilection for particular 
sites including tattoos, scars, skin piercings and sites of 
trauma. EN is not suitable for biopsy because it shows non-
specifi c panniculitis which neither confi rms nor refutes the 
diagnosis. Large extrathoracic lymph nodes can sometimes 
be easily accessible.22
If no peripheral sites are amenable to biopsy, the lungs 
and mediastinum can be sampled through endobronchial 
biopsy (EBB), peripheral transbronchial lung biopsy (TBLB), 
EBUS-TBNA or broncho-alveolar lavage (BAL) (Table 2). While 
TBLB through fl exible bronchoscopy gives access to lung 
tissue, EBUS-TBNA offers the bronchoscopist the option of 
‘looking through’ the endobronchial mucosa, visualising and 
sampling lymph nodes that were previously only accessible 
Figure 2 Causes of granulomas in lungs 
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by mediastinoscopy under general anaesthetic (Figure 3). 
This technique is both minimally invasive and safe.23 In one 
multicentre randomised trial, EBUS-TBNA samples were 
compared to conventional bronchoscopic biopsies in 304 
patients with stage I or II pulmonary sarcoidosis.24 The 
diagnostic yield for detecting granulomas was signifi cantly 
higher in the EBUS-TBNA group. In systematic analyses the 
pooled yield of EBUS-TBNA ranged from 54 to 93%.24,25 
BAL is often performed at bronchoscopy and has the 
advantage of providing cytology and microbiology samples. 
Although a lymphocytosis with elevated CD4:CD8 T-lymphocyte 
(>3.5:1) is characteristic of sarcoidosis BAL fl uid, this can be 
normal in 15% of cases.26,27
The choice of bronchoscopic investigation will be infl uenced 
by pre-test probabilities and degree of pulmonary and 
extrathoracic involvement.13 For example, in stage I 
sarcoidosis, sampling the lymph nodes via EBUS-TNA can 
have diagnostic yields of around 80% whereas the use 
of TBLB will have lower yields.28 In stage II sarcoidosis, 
TBLB has a 60% sensitivity of detecting granulomas but 
is associated with complications including haemorrhage 
and pneumothoraces.13,26 Here, the diagnostic yield can be 
increased when EBUS-TBNA is used alongside TBLB. When 
there is endobronchial mucosal involvement (in around a 
third of patients), EBB has a yield comparable to TBLB.29 In 
patients with stage III sarcoidosis, TBLB has the highest yield. 
Outcome
This patient had no skin lesions or extrapulmonary lymph 
nodes that were accessible to sampling. Blood tests were 
normal apart from lymphopenia. His lung function was 
mildly restrictive, with a forced vital capacity (FVC) of 75% 
predicted. His tuberculin skin test was negative. His HRCT 
suggested stage II disease and he proceeded to have a 
fl exible bronchoscopy under local anaesthetic with sedation 
and had EBUS-TBNA with lavage. The EBUS-TBNA samples 
demonstrated non-caseating granulomatous infl ammatory 
changes and no infection was found on BAL. The patient 
started a tapering course of oral steroids and remains 
under review.
Case scenario 3
A 49-year-old man with biopsy-proven stage II pulmonary 
sarcoidosis attends your clinic for further discussion, one 
week after his bronchoscopy with EBUS. He is keen to know 
what his prognosis is likely to be. 
Sarcoidosis can have a variable clinical course and 
this uncertainty can contribute to patient morbidity.30,31 
The Scadding classifi cation is still used for staging and 
prognostication, although imperfect. Individuals with stages III 
and IV generally have poorer outcomes.32 Unfortunately, this 
approach is not personalised and does not allow an accurate 
assessment of prognosis. Chest radiograph appearances 
alone do not distinguish between active granulomatous 
infl ammation (and consequent risk of irreversible fi brosis) 
versus ‘burnt out’ inactive disease. Furthermore, patients 
with apparently inactive Stage IV disease may have active 
disease.33
Sarcoidosis is generally not life-limiting. However, in around 
8 to 10% of patients a shortened life expectancy is primarily 
because of pulmonary involvement. In one large cohort study 
of 452 patients with sarcoidosis, age, extent of pulmonary 
fi brosis on HRCT and pulmonary hypertension (at right-heart 
catheterisation) were independent predictors of respiratory 
mortality.34 Walsh and colleagues recently developed an 
integrated prognostic scoring tool for pulmonary sarcoidosis 
incorporating physiological variables (composite physiological 
index) and HRCT imaging findings (extent of pulmonary 
fi brosis and the ratio of pulmonary artery to ascending 
aorta diameter).35 When combined, this staging system was 
strongly predictive of mortality. These models are limited in 
their ability to prognosticate in the later stages of pulmonary 
sarcoidosis. There is an urgent need for better prognostic 
biomarkers, especially in the early stages of disease.
Outcome
Our patient was reassured that while he has some minor 
fi brotic change on HRCT, this was minimal (10% extent; >20% 
considered signifi cant) and his FVC was 80% predicted. 
Furthermore, on his HRCT, pulmonary artery diameter was not 
increased i.e. similar diameter to his aorta, which together 
with a normal echocardiogram suggested no signifi cant 
pulmonary hypertension. He was reassured that he was in a 
low risk/good prognosis group. 
Type of biopsy Utility in pulmonary 
sarcoidosis
Endobronchial biopsy (EBB) Endobronchial mucosal 
involvement 
Transbronchial lung biopsy 
(TBLB)
· Stage II (sensitivity   
increased with EBUS-TNA)
· Stage III
· Endobronchial mucosal 
involvement
Endobronchial ultrasound-
guided transbronchial 
needle aspirate (EBUS-TNA)
· Stage I
· Stage II
Table 2 Application of lung biopsies and needle aspirate in 
different stages of pulmonary sarcoidosis
Figure 3 End of bronchoscope 
showing ultrasound probe and 
adjacent retractable needle 
used for lymph node sampling 
through the airway wall 
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Case scenario 4
Your conversation with the same 49-year-old man (in Case 
3) with biopsy-proven stage II pulmonary sarcoidosis moves 
on to treatment options – he wants to know if he needs 
treatment.
Patients with sarcoidosis may be managed with observation 
or immunosuppressive medications. The decision to initiate 
treatment is guided by many factors. Goals of therapy 
should be established with a risk/benefi t dialogue with the 
patient in the context of likelihood of therapeutic toxicities 
and spontaneous resolution. Notably, there is poor-quality 
evidence guiding drug choice, dose and duration. Current 
guidelines advocate initiating treatment only if there is 
potential danger of a fatal outcome, permanent disability or 
an unacceptable loss of quality of life.4,5 Most patients with 
stage I and asymptomatic stage II disease do not require 
treatment, at least initially, as there will be spontaneous 
resolution of sarcoidosis in as many as 40% of patients. 
Patients with symptomatic stage II disease, particularly if lung 
function is impaired, should be considered for drug therapy. 
If the agreed decision is to initiate drug treatment, there 
are three categories available: corticosteroids (mainly 
prednisolone), immunosuppressants (most commonly 
methotrexate, azathioprine, lefl unomide and mycophenolate) 
and biologics (mainly infl iximab).
First-line treatment
The evidence-base behind the use of corticosteroids 
in sarcoidosis is limited and the timing of initiation is 
controversial.3 For pulmonary sarcoidosis in the absence 
of life-threatening disease, some clinicians will opt for 
monotherapy with oral corticosteroids, usually starting with 
a dose of 20–40 mg of prednisolone for a month, followed by 
slow tapering to a maintenance dose, usually aiming to reach 
5–10 mg once daily (Figure 4). If there is a rapid response 
then it may be possible to begin weaning towards zero as 
early as six months. However, in most patients the response 
is slower, and weaning often begins after 12 months with 
monitoring for relapses which may necessitate reintroduction 
of higher doses. 
The toxicity risks from prolonged high-dose corticosteroids 
are considerable, notably obesity, hypertension, osteoporosis 
and diabetes mellitus.36 As a general rule of thumb, patients 
ideally should be on a maintenance dose of <10 mg 
prednisolone once daily and if they require a higher daily 
dose, or have relapsed on lower dose corticosteroids, there 
should be a very low threshold to add in a ‘steroid-sparing’ 
immunosuppressants at an early stage, even in the fi rst year. 
Second-line treatment
Before adding in another drug, it is important to review 
the diagnosis of sarcoidosis and discuss compliance with 
existing therapy. Current guidelines suggest that second-line 
therapy should be considered if there is:
a. progression of pulmonary disease or an unacceptable 
symptom burden despite adequate corticosteroids therapy
b. intolerable corticosteroids side effects
c. inability to taper corticosteroids below 10 mg prednisolone 
once daily
d. the presence of major comorbidities likely to be adversely 
affected by corticosteroids therapy 
e. a strong patient aversion to the use of corticosteroids, in 
which case a second-line drug may be occasionally used 
as an initial therapy
The most commonly used drugs are methotrexate, 
mycophenolate, lefl unomide and azathioprine. It is beyond 
the remit of this article to discuss these drug therapies in 
detail, but they are described elsewhere.3 All these drugs 
have potential for toxicity and therefore should be initiated 
only after careful thought by clinicians with expertise in their 
use, with ‘shared care’ monitoring with primary care partners. 
Third-line treatment
Patients who fail second-line therapies should be considered 
for biologic agents which block the effect of the pro-
infl ammatory cytokine tumour necrosis factor (TNF), which 
is important in granulomatous infl ammation. These drugs, 
such as infl iximab, are usually given in combination with 
second-line drugs such as methotrexate. A more detailed 
Figure 4 Example of a 
stepwise approach to initiating 
and weaning corticosteroids in 
pulmonary sarcoidosis
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discussion of TNF blockers in sarcoidosis can be found 
elsewhere.37 Interestingly, and paradoxically, case reports 
are now emerging of the development of granulomatous 
infl ammation in some patients treated with biologic immune 
checkpoint inhibitors used to treat other conditions such as 
lung cancer (pembrolizumab) and melanoma (ipilimumab).38 
Outcome 
A pro/con discussion was held with this patient regarding 
observation vs treatment. He understood that it was possible 
that his sarcoidosis might regress spontaneously, but 
equally, if his disease progressed with further granulomatous 
inflammation, he might develop potentially irreversible 
fi brotic change. He was also advised that corticosteroids 
would have a useful anti-infl ammatory effect in his lungs, but 
carried potential for toxicity. His preference was for a more 
conservative initiation dose of 20 mg of prednisolone once 
daily with a slow taper to 7.5 mg once-daily maintenance. 
A bone density scan was performed at baseline (normal) 
and he was specifically counselled about reporting any 
dyspepsia. He remained well throughout treatment. At nine 
months, symptoms settled completely and chest radiograph 
was normal. His corticosteroid dose was therefore weaned 
by 1 mg each month thereafter, and he had three-monthly 
clinic reviews with chest radiograph and detailed pulmonary 
function tests. He managed to wean and discontinue 
corticosteroids and remains under regular clinic review, 
mindful of the risk of relapse. 
If relapse did occur, we would re-initiate corticosteroids, again 
with weaning, but would also add in a second-line treatment. 
Our preference is once-weekly methotrexate with folic acid. 
The aim is to allow the corticosteroids dose to be gradually 
weaned, below 10 mg once daily. We tend to continue 
methotrexate, if tolerated, for a minimum of two years, and 
then reassess.39 
Case scenario 5
A 60-year-old female with pulmonary sarcoidosis has 
been on oral corticosteroids for 18 months and describes 
profound fatigue, low mood and breathlessness on attempts 
to wean her prednisolone dose below 10 mg daily. She has 
gained 9 kg in weight since being on treatment. You are 
unsure if her sarcoidosis is ‘active’ or she has become 
deconditioned. Her chest radiograph notes stage II disease 
and appears unchanged. Are there tools to help assess 
disease activity?
This is a common clinical situation. It is possible that she 
still has inadequately treated pulmonary sarcoidosis, the 
danger being progressive and irreversible lung fibrosis. 
Therefore, it may be that she needs additional therapy.39–42 
Equally, it is possible that she has become deconditioned 
through corticosteroid-associated weight gain and myopathy, 
and further attempts at corticosteroid weaning should 
occur. Fatigue and depression are common in patients 
with sarcoidosis, often not fully acknowledged by treating 
clinicians, with little high-quality evidence for treatment.43,44 
It is also possible that there are other causes for her 
symptoms, including unrecognised cardiac sarcoidosis,45,46 
pulmonary hypertension,47 or sleep apnoea.48
Unfortunately, no perfect tool exists to assess sarcoidosis 
activity. In routine clinical practice it is often estimated by 
integrating clinical history (symptoms), physiology (trends in 
lung function such as FVC) and radiology (chest radiograph 
± HRCT).17 
In carefully selected patients, a PET scan can be considered, 
using 18F-FDG which has high uptake in inflammatory 
disorders and malignant lesions.49 PET appears especially 
helpful in those persistently symptomatic patients without 
serological signs of infl ammatory activity, in patients with 
radiological signs of fi brosis and in the detection of active 
cardiac sarcoidosis. PET is also sometimes used to uncover 
a suitable location for biopsy to obtain histological evidence 
for the diagnosis and explain extrathoracic symptoms.49–51
Suggested strategy
1. Full assessment as discussed in  Case 2. In addition, 
thyroid function tests will exclude hypothyroidism and the 
possibility of cardiac involvement/pulmonary hypertension 
should be considered (ECG, echocardiogram and, if 
ongoing concern, cardiac magnetic resonance imaging). 
2. Sleep assessment: Epwor th Sleepiness Scale 
Questionnaire and overnight sleep study – obstructive 
sleep apnoea is common in sarcoidosis and this patient’s 
increased weight is a predisposing risk factor. 
3. PET: as discussed earlier, defi nitely not a fi rst-line test, 
but may be useful in carefully selected patients. 
Outcome
Blood tests were normal apart from mild lymphopenia. 
There was no evidence of cardiac disease or pulmonary 
hypertension on ECG and echocardiogram. A sleep study 
was normal. Her PET scan, however, noted fl orid pulmonary 
parenchymal uptake of FDG (Figure 5), without evidence of 
abnormal cardiac FDG uptake. Her sarcoidosis was therefore 
assumed to be still active and she was started on once-
weekly methotrexate and folic acid. After three months her 
corticosteroid was gradually weaned to 5 mg once daily and 
by six months had been stopped. She regained her pre-
diagnosis weight, was seen by a physiotherapist, and enrolled 
in pulmonary rehabilitation classes, which reduced fatigue. 
Methotrexate was discontinued after two years following a 
second PET scan at that time noting no ongoing activity.
Conclusion
There have been major advances in the management of 
sarcoidosis during the last decade. Nonetheless, many 
aspects of care remain challenging, and in our review we 
have used clinical vignettes to explore these further. Key 
learning points include: 
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• A diagnosis of sarcoidosis can be made without a biopsy 
in the context of an appropriate clinical history and chest 
imaging. 
• EBUS-TNA is now routinely used for bronchoscopic 
sampling in patients with suspected sarcoidosis. It 
gives access to lymph nodes that were previously only 
accessible by mediastinoscopy.
• Steroid-sparing therapies, such as methotrexate, should 
be considered early in patients at risk of corticosteroid-
induced toxicities.
•  18F-FDG PET scans can be useful in carefully selected 
patients to help distinguish active pulmonary sarcoidosis 
from other differential diagnoses. 
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